Medical/Pharmaceuticals
China's Largest Commercial GMP Plasmid Manufacturing Facility is Put into Operation, GenScript ProBio Expanding Manufacturing Capacity Again
ZHENJIANG, China, Dec. 7, 2021 /PRNewswire/ -- On December 7th, the "Opening
Ceremony ofGenScript ProBio
2021-12-07 21:33
2397
Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting
HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual Gene...
2021-12-07 21:32
3381
I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited
SHANGHAI and GAITHERSBURG, Md., Dec. 7, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Board of Directors of the Company (the "Board") ...
2021-12-07 21:00
5289
SyMap Medical Ltd. Closes Largest Financing Round in Renal Denervation Field
SUZHOU, China, Dec. 7, 2021 /PRNewswire/ -- SyMap Medical (SyMap) announced its latest financing round of nearly$100 million led by Primavera Capital and VMS Group, with the participation of existing investors Simiao Equity Investment and Sequoia Capital China. CEC Capital served as the exclusive...
2021-12-07 20:30
2891
Samsung Biologics adds to global ISO certifications with Quality Management System
* Samsung Biologics earns ISO9001 for Quality Management System, proving its capabilities to ensure high-quality service offerings throughout a product life-cycle * The company is fully certified with the recognition across all of its CDO, CMO and all other core business units in Plant 1,2, a...
2021-12-07 13:04
2801
Akeso Announces Launch of U.S. Investigator-Initiated Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody)
HONG KONG, Dec. 6, 2021 /PRNewswire/ -- Today, Akeso, Inc. (9926.HK) announced that the company will support an investigator-initiated study (IIS) to evaluate the efficacy and safety of Akeso's novel, first-in-class anti-PD-1/CTLA-4 bispecific antibody, cadonilimab, for the treatment of neuroendo...
2021-12-07 08:20
2718
IMPACT 2021 R&D Day: Synthetic Lethality Provides a New Platform for Targeted Cancer Therapy
SHANGHAI, Dec. 6, 2021 /PRNewswire/ -- The 2nd R&D Day event of IMPACT Therapeutics (IMPACT) successfully took place inShanghai on December 3rd (GMT+8). With the theme of "Synthetic Lethality: A New Platform for Targeted Therapy", the event attracted nearly 300 guests offline and online. The gues...
2021-12-06 16:03
2592
Odyssey Announces Agreement to Combine with BenevolentAI
* BenevolentAI is a leading, clinical-stage AI drug discovery company that combines advanced AI and machine learning with cutting edge science to discover and develop novel and more effective medicines * Combination of BenevolentAI with Odyssey, a €300m Euronext Amsterdam-listed special purpo...
2021-12-06 14:00
11432
Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China
BEIJING and SHANGHAI and BOSTON, Dec. 5, 2021 /PRNewswire/ -- Jacobio Pharma ( 1167.HK) has received the Investigational New Drug (the "IND") approval of the combination therapy of KRAS G12C inhibitor JAB-21822 and Cetuximab injection from the Center for Drug Evaluation ofChina (the "CDE") on Dec...
2021-12-06 09:16
3236
Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma
SYDNEY, Dec. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The res...
2021-12-04 21:00
5604
I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Dec. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first two patients have been dosed in the U.S. p...
2021-12-03 21:00
4249
OrigiMed announced its strategic partnership with Janssen to develop clinical innovative solutions driven by data science
SHANGHAI, Dec. 3, 2021 /PRNewswire/ -- OrigiMed Co., Ltd. ("OrigiMed") announced that the company has signed a memorandum of understanding (MoU) on strategic collaboration with Janssen (China) Research and Development Center of Johnson & Johnson (China) Investment Co., Ltd. ("Janssen").Zili Li, M...
2021-12-03 17:01
6328
Biotheus' Bifunctional Therapeutic PM8001 has been Approved by the USFDA to Enter Phase II Studies
ZHUHAI, China, Dec. 3, 2021 /PRNewswire/ -- Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA (United States Food and Drug Administration) for conducting clinical phase II studies as part of an international m...
2021-12-03 16:23
2543
InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List
BEIJING, Dec. 2, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement Drug List (NRDL) by the China National Healthcare Security Administration (NHSA). ...
2021-12-03 10:13
2878
Hepagene Therapeutics Initiates the RISE Study, a Phase IIa Clinical Trial of HPG1860 in Patients with NASH
SHANGHAI, Dec. 2, 2021 /PRNewswire/ -- Hepagene Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on innovative therapies for patients with liver diseases, today announced that it has screened the first patient in theUSA for the RISE study, a Phase IIa clinical trial of HPG18...
2021-12-02 23:00
2158
MingMed Biotechnology Announces U.S. FDA Approval for IND Application of HPK1 Small Molecule Inhibitor PRJ1-3024, and Completion of Phase I Clinical Trials for Dry AMD Treatment Drug QA102
GUANGZHOU, China, Dec. 2, 2021 /PRNewswire/ -- MingMed Biotechnology, a clinical stage company dedicated to developing first-in-class pharmaceutical products, announced recently the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for PRJ1-3024, a ...
2021-12-02 22:00
2304
Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics
SYDNEY, Dec. 2, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and Cardinal Health (NYSE: CAH), are pleased to announce that the companies have entered ...
2021-12-02 21:58
2869
Rayence's Low-Dose Detector "GreenON" Receives Critical Acclaim at RSNA 2021
SEOUL, South Korea, Dec. 2, 2021 /PRNewswire/ -- Rayence(www.rayence.com
2021-12-02 21:30
2945
DiNovA Medtech Announces Mr. Yaniv Kirma to Join as DiNovA Israel Incubator's Chief Operating Officer
CAESAREA, Israel, Dec. 2, 2021 /PRNewswire/ -- DiNovA Medtech, a leading medical devices incubator inChina ("DiNovA"), is pleased to announce Mr. Yaniv Kirma, to come on board as Chief Operating Officer of DiNovA Israel Incubator ("DiNovA Israel"). Mr. Kirma will join force with Chief Medical Off...
2021-12-02 16:00
2498
Fifty percent recruitment milestone for PROPELLER prostate cancer trial
SYDNEY, Dec. 1, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that 15 of 30 participants have been recruited in the diagnostic64...
2021-12-01 21:57
2573
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 294 media titles]
2026-09-24 10:30
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 278 media titles]
2026-09-29 09:00
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 278 media titles]
2026-09-28 23:04
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45
Nuix Recognised as a RiskTech100® 2027 Disruptor by Chartis Research
[Picked up by 274 media titles]
2026-09-25 08:30Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
13883
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
12600
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
11636
